Recent posts

Biopharma Data: Chaos or Harmony?

By January 29, 2018

If data can throw your biotherapeutic development program into chaos, it can also help move you forward. Let’s see how.

Categories: Pharmaceutical
Tags: , , , , , , , ,

From Characterization to Late Development, Manufacturing, and QC: The Expanding Role of Mass Spectrometry in Biotherapeutics

By January 26, 2018

The improvements in LC-MS technology under GxP compliant-ready informatics for biopharmaceutical analysis has prepared the industry to expand the role of MS technologies beyond product characterization toward monitoring product and process quality attributes.

Categories: Pharmaceutical
Tags: , , , , ,

Oligo-mania! Interest in Oligonucleotides Continues to Rise

By July 7, 2017

From oligonucleotides and peptides to messenger RNA and CRISPR, ’tides are enjoying their time in the sun A year ago we wrote how oligonucleotide therapeutic development, which had seen a huge wave of investment in… Read more >

Categories: Pharmaceutical
Tags: , , , ,

A Leading CRO’s Customer Focus Leads to Improvements in Quality and Productivity

By April 25, 2017

“One of the important reasons that we use Waters LC-MS instruments is that beyond the quality of the products, Waters delivers a high degree of technical training. This provides us with the knowledge and confidence that we can solve our complex research questions.” comments Triskelion’s Richard Bas.

Categories: Customer Stories, Pharmaceutical
Tags: , , , , , , ,

A CRO Leads the Way for Biotherapeutics Amid its Own ‘Field of Dreams’

By January 16, 2017

“If You Build it, He Will Come” Urged on by a voice no one else could hear, Ray Kinsella, played by Kevin Costner in the movie Field of Dreams, cleared a few acres of corn… Read more >

Categories: Customer Stories, Pharmaceutical
Tags: , , ,

Analytical Tools for Developing Biosimilars: Part 3, Glycosylation, Aggregation, and Charge Variants

By January 13, 2017

In biotherapeutics, the state of glycosylation has a direct and pronounced effect of the structure, stability, serum half-life, immunogeneicity and bioactivity of the molecule, and constitutes a critical quality attribute (CQA). In our study, characterizing and comparing the glycosylation profile of infliximab began by examining the glycosylation profiles from intact and reduced subunit mass data.

Categories: Pharmaceutical
Tags: , , , , , , , , , ,

Analytical Tools for Developing Biosimilars: Part 2, Peptide Analysis

By January 13, 2017

Advancements in High-Resolution Analytics for Characterization of Innovator and Biosimilar Therapeutics Part 2: Peptide Analysis of Infliximab

Categories: Pharmaceutical
Tags: , , , , , ,

How Analytical Technologies Support the Development of Biosimilar Drugs

By January 12, 2017

Advancements in High-Resolution Analytics for the Characterization of Innovator and Biosimilar Therapeutics As the pharmaceutical industry continues to evolve its focus from small-molecule drugs to balanced product portfolios that include protein therapeutics, analytical chemists are… Read more >

Categories: Pharmaceutical
Tags: , , , , , , , , , ,

Infographic: Large Molecules Have a 2X Greater FDA Approval Rate Than Small Molecule Drugs

By November 23, 2016

It’s no surprise that pharma is ‘Thinking Large’ Large molecules are dominating pharma sales and FDA approvals. At the end of 2015, seven of the top 10 best-selling prescription drugs were large molecules. According to a 2014 article… Read more >

Categories: Pharmaceutical
Tags: , , , ,

Webinar Highlights: Microfluidics for Macromolecules

By November 14, 2016

Hi, I’m Jim Murphy, Principal Consulting Chemist at Waters, and I recently collaborated with Lucinda (Cohen) Hittle to present an exciting BioanalysisZone webinar on the use of microflow chromatography for macromolecules. Lucinda, a Director of… Read more >

Categories: Pharmaceutical, Technologies
Tags: , , ,